vs
GrowGeneration Corp.（GRWG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
GrowGeneration Corp.的季度营收约是REGENXBIO Inc.的1.2倍（$37.8M vs $30.3M），GrowGeneration Corp.净利率更高（-19.6% vs -221.3%，领先201.7%），REGENXBIO Inc.同比增速更快（43.0% vs 1.0%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -11.1%）
GrowGeneration Corp是美国领先的水培及有机园艺用品专业零售商，主营种植灯、营养液、环境控制系统、栽培工具等全系列产品，通过覆盖全国的实体门店和电商渠道，为商业室内种植从业者（包括合法大麻种植商）及家庭园艺爱好者提供服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GRWG vs RGNX — 直观对比
营收规模更大
GRWG
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出42.0%
1.0%
净利率更高
GRWG
高出201.7%
-221.3%
两年增速更快
RGNX
近两年复合增速
-11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.8M | $30.3M |
| 净利润 | $-7.4M | $-67.1M |
| 毛利率 | 24.1% | — |
| 营业利润率 | -20.1% | -190.0% |
| 净利率 | -19.6% | -221.3% |
| 营收同比 | 1.0% | 43.0% |
| 净利润同比 | 68.2% | -31.2% |
| 每股收益（稀释后） | $-0.12 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GRWGRGNX
| Q4 25 | $37.8M | $30.3M | ||
| Q3 25 | $47.3M | $29.7M | ||
| Q2 25 | $41.0M | $21.4M | ||
| Q1 25 | $35.7M | $89.0M | ||
| Q4 24 | $37.4M | $21.2M | ||
| Q3 24 | $50.0M | $24.2M | ||
| Q2 24 | $53.5M | $22.3M | ||
| Q1 24 | $47.9M | $15.6M |
净利润GRWGRGNX
| Q4 25 | $-7.4M | $-67.1M | ||
| Q3 25 | $-2.4M | $-61.9M | ||
| Q2 25 | $-4.8M | $-70.9M | ||
| Q1 25 | $-9.4M | $6.1M | ||
| Q4 24 | $-23.3M | $-51.2M | ||
| Q3 24 | $-11.4M | $-59.6M | ||
| Q2 24 | $-5.9M | $-53.0M | ||
| Q1 24 | $-8.8M | $-63.3M |
毛利率GRWGRGNX
| Q4 25 | 24.1% | — | ||
| Q3 25 | 27.2% | — | ||
| Q2 25 | 28.3% | — | ||
| Q1 25 | 27.2% | — | ||
| Q4 24 | 16.4% | 70.2% | ||
| Q3 24 | 21.6% | 48.8% | ||
| Q2 24 | 26.9% | 52.5% | ||
| Q1 24 | 25.8% | 72.6% |
营业利润率GRWGRGNX
| Q4 25 | -20.1% | -190.0% | ||
| Q3 25 | -6.0% | -176.3% | ||
| Q2 25 | -12.9% | -296.3% | ||
| Q1 25 | -27.7% | 13.6% | ||
| Q4 24 | -63.9% | -242.1% | ||
| Q3 24 | -24.2% | -256.6% | ||
| Q2 24 | -12.2% | -251.3% | ||
| Q1 24 | -19.7% | -408.8% |
净利率GRWGRGNX
| Q4 25 | -19.6% | -221.3% | ||
| Q3 25 | -5.2% | -208.3% | ||
| Q2 25 | -11.7% | -331.8% | ||
| Q1 25 | -26.3% | 6.8% | ||
| Q4 24 | -62.4% | -241.3% | ||
| Q3 24 | -22.9% | -246.3% | ||
| Q2 24 | -11.0% | -237.7% | ||
| Q1 24 | -18.5% | -405.4% |
每股收益（稀释后）GRWGRGNX
| Q4 25 | $-0.12 | $-1.30 | ||
| Q3 25 | $-0.04 | $-1.20 | ||
| Q2 25 | $-0.08 | $-1.38 | ||
| Q1 25 | $-0.16 | $0.12 | ||
| Q4 24 | $-0.39 | $-0.99 | ||
| Q3 24 | $-0.19 | $-1.17 | ||
| Q2 24 | $-0.10 | $-1.05 | ||
| Q1 24 | $-0.14 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $46.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $97.5M | $102.7M |
| 总资产 | $147.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GRWGRGNX
| Q4 25 | $46.1M | $230.1M | ||
| Q3 25 | $48.3M | $274.2M | ||
| Q2 25 | $48.7M | $323.3M | ||
| Q1 25 | $52.6M | $267.9M | ||
| Q4 24 | $56.5M | $234.7M | ||
| Q3 24 | $55.2M | $255.5M | ||
| Q2 24 | $56.0M | $290.4M | ||
| Q1 24 | $61.3M | $338.7M |
股东权益GRWGRGNX
| Q4 25 | $97.5M | $102.7M | ||
| Q3 25 | $104.7M | $161.5M | ||
| Q2 25 | $106.7M | $213.7M | ||
| Q1 25 | $111.2M | $274.2M | ||
| Q4 24 | $120.1M | $259.7M | ||
| Q3 24 | $143.2M | $301.4M | ||
| Q2 24 | $155.8M | $348.3M | ||
| Q1 24 | $165.3M | $390.7M |
总资产GRWGRGNX
| Q4 25 | $147.0M | $453.0M | ||
| Q3 25 | $159.6M | $525.2M | ||
| Q2 25 | $160.6M | $581.0M | ||
| Q1 25 | $164.2M | $490.9M | ||
| Q4 24 | $174.4M | $466.0M | ||
| Q3 24 | $199.6M | $519.1M | ||
| Q2 24 | $219.2M | $569.4M | ||
| Q1 24 | $230.4M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GRWGRGNX
| Q4 25 | $-2.2M | $-52.3M | ||
| Q3 25 | $-499.0K | $-56.0M | ||
| Q2 25 | $-2.9M | $-49.3M | ||
| Q1 25 | $-3.8M | $33.6M | ||
| Q4 24 | $1.1M | $-31.6M | ||
| Q3 24 | $1.2M | $-40.5M | ||
| Q2 24 | $-398.0K | $-45.5M | ||
| Q1 24 | $-3.6M | $-55.5M |
自由现金流GRWGRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率GRWGRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度GRWGRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率GRWGRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GRWG
| Consumables | $22.3M | 59% |
| Durables | $9.8M | 26% |
| Commercial Fixture Sales | $5.7M | 15% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
